Highbridge Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Highbridge Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-14,110	Closed	-$674K	–	720
2021 Q4	$674K	Buy	+14,110	New	+$972K	0.01%	407
2017 Q2	–	Sell	-340	Closed	-$856K	–	1701
2017 Q1	$856K	Buy	+340	New	+$979K	0.01%	671
2016 Q2	–	Sell	-409	Closed	-$1.3M	–	1835
2016 Q1	$1.3M	Buy	409 +35	+9%	+$145K	0.02%	648
2015 Q4	$1.92M	Buy	+374	New	+$1.63M	0.03%	538
2015 Q2	–	Sell	-1,651	Closed	-$6.59M	–	1735
2015 Q1	$6.59M	Buy	+1,651	New	+$7.56M	0.09%	259
2014 Q4	–	Sell	-191	Closed	-$777K	–	1498
2014 Q3	$777K	Buy	191 +117	+158%	+$439K	0.01%	744
2014 Q2	$298K	Buy	+74	New	+$302K	﹤0.01%	871
2014 Q1	–	Sell	-174	Closed	-$609K	–	1295
2013 Q4	$609K	Sell	174 -501	-74%	-$1.95M	0.01%	627
2013 Q3	$2.77M	Buy	675 +597	+765%	+$2.57M	0.03%	447
2013 Q2	$310K	Buy	+78	New	+$321K	﹤0.01%	1027

Other funds holding ACOR

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCA

Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Highbridge Capital Management's ACOR Position: Q1 2022 in Review

Highbridge Capital Management sold out of Acorda Therapeutics (ACOR) in Q1 2022, closing a stake of 14,110 shares — an estimated $674K sold.

Highbridge Capital Management first reported a position in ACOR in Q2 2013 and held it in 10 quarters. The position peaked at $6.59M in Q1 2015. 31 funds tracked by Wall St. Rank hold ACOR as of Q1 2022.

Highbridge Capital Management reported no remaining Acorda Therapeutics position as of Q1 2022 after selling out during the quarter.
Highbridge Capital Management sold 14,110 Acorda Therapeutics shares in Q1 2022, an estimated $674K.
Highbridge Capital Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 10 quarters.
Highbridge Capital Management's Acorda Therapeutics position peaked at $6.59M in Q1 2015.
31 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2022.

Based on Highbridge Capital Management's 13F filing for Q1 2022, filed 11 May 2022.